It does not prove that NWBO paid for InMune. The facility belonged to another party. My sense of it is actually other parties used the space as well. NEBO likely had dedicated space with Advent for its production.
If Advent then went on to do other manufacturing on site, it may not have been in the same space and likely not with the same exact tools or machinery for which NWBO was billed. My point is that it is not likely that your language means necessarily what you said in your summary in other words. It is easy to take a very general description and abstract it into another meaning.
NWBO paid Advent to lease space for its production, Advent made product for InMune (taking your word for it) at the same facility, ergo NWBO paid for InMune product. Those things are not necessarily true. The space did not belong to them. Advent is a contract manufacturer. I can’t imagine that they are so sloppy that they are mixing up production spaces in a GMP facility.
I just think you take these assumptions as far as you can possibly take them to suggest bad behavior that seems unlikely.
It is also possible that there are more complex arrangements going on, that have not been fully explicated by that text. But you have assumed the worst possible interpretation to advance these theories.
Market Data 
Markets 
AI
